This study is testing how effective a new vaccine is in preventing respiratory infections caused by the respiratory syncytial virus (RSV).
Respiratory syncytial virus (RSV) is a common seasonal virus that infects the airways of the lungs. Some people, especially older adults or those living with some long-term conditions, can experience serious complications, including inflammation of the lungs of pneumonia.
This international study is being carried out in Greater Manchester by a team of researchers at Manchester University NHS Foundation Trust.
- aged 60+
- no serious illness that is not under control with medication
- no history of anaphylaxis or allergic reactions to vaccines
Taking part will involve:
- Attending at least four clinic visits and two telephone calls over a 19-month period.
- Clinic visits will include a range of tests (eg blood samples, heart and blood pressure checks) as well as questions about lifestyle and medical history
- Completing a weekly diary of any respiratory symptoms.
- Receiving a new vaccine*
* Participants will be randomly selected to receive either the new vaccine or a placebo.